Eli Lilly and Company $LLY Shares Bought by IFM Investors Pty Ltd

Key Points

• IFM Investors Pty Ltd increased its holdings in Eli Lilly and Company by 3.9%, boosting its total shares to 158,272 and making it the fund's 11th largest holding.
• Eli Lilly's recent quarterly earnings report showed an EPS of $6.31, surpassing analyst estimates of $5.59, with a year-over-year revenue growth of 37.6%.
• The company declared a quarterly dividend of $1.50 per share, resulting in an annualized dividend of $6.00 and yielding 0.8%.

IFM Investors Pty Ltd lifted its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 3.9% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 158,272 shares of the company's stock after buying an additional 5,972 shares during the quarter. Eli Lilly and Company makes up approximately 1.2% of IFM Investors Pty Ltd's portfolio, making the stock its 11th biggest position. IFM Investors Pty Ltd's holdings in Eli Lilly and Company were worth $123,378,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in LLY. Brighton Jones LLC raised its holdings in shares of Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock valued at $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC increased its holdings in Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock valued at $1,136,000 after buying an additional 40 shares during the last quarter. Bank Pictet & Cie Europe AG raised its stake in Eli Lilly and Company by 4.1% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 64,758 shares of the company's stock valued at $49,993,000 after buying an additional 2,568 shares in the last quarter. Breed s Hill Capital LLC lifted its holdings in Eli Lilly and Company by 212.0% during the 4th quarter. Breed s Hill Capital LLC now owns 1,426 shares of the company's stock worth $1,101,000 after buying an additional 969 shares during the last quarter. Finally, Headinvest LLC boosted its position in shares of Eli Lilly and Company by 13.2% during the 4th quarter. Headinvest LLC now owns 790 shares of the company's stock worth $610,000 after acquiring an additional 92 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently commented on LLY shares. JPMorgan Chase & Co. dropped their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating on the stock in a report on Tuesday. Erste Group Bank lowered shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. Hsbc Global Res upgraded shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research report on Wednesday, August 27th. Cantor Fitzgerald dropped their target price on shares of Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 13th. Finally, Berenberg Bank reiterated a "hold" rating and set a $830.00 price target (down from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $939.61.

Insider Buying and Selling

In other news, EVP Daniel Skovronsky acquired 1,000 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the transaction, the executive vice president directly owned 137,660 shares in the company, valued at approximately $87,331,504. This represents a 0.73% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Gabrielle Sulzberger acquired 117 shares of the business's stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $641.18 per share, with a total value of $75,018.06. Following the transaction, the director owned 2,703 shares in the company, valued at $1,733,109.54. The trade was a 4.52% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock traded down $9.41 during trading on Friday, reaching $753.52. The company's stock had a trading volume of 7,319,147 shares, compared to its average volume of 3,181,974. The company has a 50-day moving average price of $738.37 and a two-hundred day moving average price of $770.79. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $939.86. The firm has a market cap of $713.18 billion, a PE ratio of 49.25, a P/E/G ratio of 1.05 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company's quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th were given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend was Friday, August 15th. Eli Lilly and Company's dividend payout ratio (DPR) is presently 39.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.